Back to News
Market Impact: 0.18
Alzamend Regains Compliance With Nasdaq Equity Requirement
Source: Nasdaq
Regulation & LegislationHealthcare & BiotechCompany Fundamentals
Alzamend Neuro received Nasdaq confirmation that it has regained compliance with the exchange's minimum equity requirement for continued listing. The notice removes an immediate delisting-compliance risk for the clinical-stage biopharmaceutical company, though no financial figures or operating updates were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ALZN0.45
More News
- UN mission finds evidence of U.S. war crimes in Iran; Washington rejects report
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year